Delivery Order SPE2DB24D2101-SPE2DB25FKMVH
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL medication. This is a firm fixed-price delivery order valued at $33,364.14, with an ultimate completion date of July 22, 2025. The award carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for supply of HUMIRA (CF) Pen 40 mg/0.4 mls with a ceiling value of $30,231.93. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract with an ultimate completion date of July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill the performance...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKMVHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies a comprehensive range of pharmaceutical products and medical supplies to support military and federal healthcare systems. The company serves as a critical vendor for the Defense Logistics Agency's Medical Supply Chain, providing brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. Under this specific delivery order, the company is supplying HUMIRA (adalimumab), a biologic immunosuppressant medication commonly used to treat autoimmune conditions, to support Department of Defense and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/28/25 |